type 2 diabetes

J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?
J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?
Fierce Pharma
JNJ
Invokana
diabetic kidney disease
FDA
type 2 diabetes
Flag link:
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Fierce Pharma
Novo Nordisk
oral semaglutide
FDA
Rybelsus
type 2 diabetes
Flag link:
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Fierce Biotech
Novo Nordisk
e-therapeutics
drug discovery
type 2 diabetes
Flag link:
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
Flag link:
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Yahoo/Zacks.com
Eli Lilly
clinical trials
type 2 diabetes
Trulicity
Flag link:
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Pharmaforum
Novo Nordisk
Victoza
type 2 diabetes
pediatric
Flag link:
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
Flag link:
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Pharmaforum
Novo Nordisk
type 2 diabetes
diabetes
chronic kidney disease
Flag link:
Insulin Patch Earns Spot in American Diabetes Association Guidelines for Diabetes Care
Insulin Patch Earns Spot in American Diabetes Association Guidelines for Diabetes Care
Xtalks
diabetes
type 2 diabetes
insulin patch
ADA
Valeritas
V-Go
devices
Flag link:
Oramed spearheading human oral insulin trials in 37 US centers
Oramed spearheading human oral insulin trials in 37 US centers
CP Wire
Oramed
insulin
oral insulin
diabetes
type 2 diabetes
clinical trials
Flag link:
Oramed spearheading human oral insulin trials in 37 US centers
Oramed
insulin
type 2 diabetes
diabetes
clinical trials
oral insulin
Flag link:
FDA approves AstraZeneca's triple combination therapy for type 2 diabetes
FDA approves AstraZeneca's triple combination therapy for type 2 diabetes
Healio
AstraZeneca
type 2 diabetes
FDA
Qternmet XR
Flag link:
Novo seeks Victoza label expansion with fresh pediatric trial results
Novo seeks Victoza label expansion with fresh pediatric trial results
Biopharma Dive
Novo Nordisk
type 2 diabetes
pediatrics
Victoza
Flag link:
BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
Fierce Biotech
Eli Lilly
Boehringer Ingelheim
Jardiance
type 2 diabetes
heart failure
Flag link:
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Pharmaforum
Poxel
Japan
diabetes
type 2 diabetes
clinical trials
imeglimin
Flag link:
Intarcia licenses Numab's autoimmune therapy
Intarcia licenses Numab's autoimmune therapy
BioCentury
Intarcia
Numab
BD016
type 2 diabetes
Flag link:
AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR
AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR
Pharmaceutical Business Review
AstraZeneca
type 2 diabetes
Farxiga
Xigduo XR
FDA
Flag link:
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655
Flag link:
FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns
FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns
BioSpace
Zafgen
clinical trials
FDA
diabetes
ZGN-1061
type 2 diabetes
Flag link:

Pages